ArticleThe British journal of ophthalmology2022
Evaluation of intravitreal topotecan dose levels, toxicity and efficacy for retinoblastoma vitreous seeds: a preclinical and clinical study.
Article in The British journal of ophthalmology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06425419 (The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy), which is not on this map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy
Who cites it
20 citing papers in PubMed, 39 citations in OpenAlex.
- Topotecan Synergizes with SP141 in the Management of Uveal Melanoma.bioRxiv : the preprint server for biology · 2026Article
- Topotecan Microneedle Scleral Patch: A Transscleral Drug Delivery Study for Retinoblastoma.Ophthalmology science · 2026Article
- In Vitro Stability and Preclinical Safety Evaluation of High-Dose Intravitreal Topotecan in Rabbits: Impact of Dose and Concentration.Ophthalmology science · 2026Article
- Stability study of topotecan in ophthalmic prefilled syringes for intravitreal delivery.European journal of hospital pharmacy : science and practice · 2025Article
- High-dose topotecan (90 and 180 μG) for recurrent subretinal and vitreous seeding in retinoblastoma.American journal of ophthalmology case reports · 2025Article
- Role of additional topotecan injections (plus two) in reducing recurrence rate in retinoblastoma of group D and group E patients: a retrospective study.BMJ open ophthalmology · 2025Article
- HIGH-DOSE INTRAVITREAL TOPOTECAN (100 µ G/0.1 CC) AS MONOTHERAPY FOR RECURRENT/REFRACTORY INTRAOCULAR RETINOBLASTOMA IN SEVEN EYES.Retina (Philadelphia, Pa.) · 2025Article
- Update on Retinoblastoma Therapies.Medicina (Kaunas, Lithuania) · 2025Review
- The Contribution of Nanomedicine in Ocular Oncology.Cancers · 2025Review
- Histone Deacetylases in Retinoblastoma.International journal of molecular sciences · 2024Review
- Aqueous VEGF-A Levels as a Liquid Biopsy Biomarker of Retinoblastoma Vitreous Seed Response to Therapy.Investigative ophthalmology & visual science · 2024Article
- Advanced Interventional Treatments in Retinoblastoma Management: A Comprehensive Review.Cardiovascular and interventional radiology · 2024Review
- Emerging New Therapeutics for Retinoblastoma.Ocular oncology and pathology · 2022Review
- Ocular and systemic toxicity of high-dose intravitreal topotecan in rabbits: Implications for retinoblastoma treatment.Experimental eye research · 2022Article
- The Role of Cryotherapy in Vitreous Concentrations of Topotecan Delivered by Episcleral Hydrogel Implant.Pharmaceutics · 2022Article
- Treatment of Retinoblastoma: What Is the Latest and What Is the Future.Frontiers in oncology · 2022Review
- Intravitreal HDAC Inhibitor Belinostat Effectively Eradicates Vitreous Seeds Without Retinal Toxicity In Vivo in a Rabbit Retinoblastoma Model.Investigative ophthalmology & visual science · 2021Article
- Efficacy, Toxicity, and Pharmacokinetics of Intra-Arterial Chemotherapy Versus Intravenous Chemotherapy for Retinoblastoma in Animal Models and Patients.Translational vision science & technology · 2021Article
- Article
- Suprachoroidal Injection of Topotecan for Retinoblastoma: A Preclinical Study.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundCurrent melphalan-based intravitreal regimens for retinoblastoma (RB) vitreous seeds cause retinal toxicity. We assessed the efficacy and toxicity of topotecan monotherapy compared with melphalan in our rabbit model and patient cohort.
methodsRabbit experiments: empiric pharmacokinetics were determined following topotecan injection. For topotecan (15 μg or 30 µg), melphalan (12.5 µg) or saline, toxicity was evaluated by serial electroretinography (ERG) and histopathology, and efficacy against vitreous seed xenografts was measured by tumour cell reduction and apoptosis induction. PATIENTS: retrospective cohort study of 235 patients receiving 990 intravitreal injections of topotecan or melphalan.
resultsIntravitreal topotecan 30 µg (equals 60 µg in humans) achieved the IC
conclusionsTaken together, these experiments suggest that intravitreal topotecan monotherapy for the treatment of RB vitreous seeds is non-toxic and effective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.